Vigorously promote the development of the biomedical industry, and release 2025 goals in many places!

【Pharmaceutical Network Policies and Regulations】With the in-depth development of a new round of scientific and technological revolution and industrial transformation, the global life sciences are changing with each passing day, biotechnology is accelerating iteration, and the biomedical industry has entered a high-growth channel
.
It is worth noting that at the same time, the industry has also begun to become a new track
for the layout of various places in China.
Recently, the General Office of the Shanghai Municipal People's Government issued Several Policies and Measures for Shanghai to Accelerate the Construction of a Global Biomedical R&D Economic and Industrialization Highland.

It mentioned that by 2025, Shanghai's global biomedical R&D economy and industrialization highland development pattern will initially take shape, the overall scale of R&D economy will reach more than 100 billion yuan, cultivate or introduce more than 100 innovative drugs and medical device blockbuster products, cultivate more than 50 innovative headquarters with compound functions such as biomedical R&D, sales, and settlement, cultivate more than 20 high-level biomedical incubators and accelerators, and promote the listing and trading of more than 1,000 biomedical patents in Shanghai.
More than 5 biomedical municipal engineering research centers have been newly deployed to provide innovative services
such as engineering verification and transformation for more than 100 early high-quality achievements of universities and research institutes.
It is worth mentioning that at the Zhangjiang Life Science International Innovation Summit held earlier, the "Pudong New Area Action Plan for Promoting the Development of Cell and Gene Therapy Industry (2023-2025)"
was also released.
On the "new track" of biomedicine, Pudong has also set a goal: by 2025, 4-5 new innovative products will be added, of which 1-2 will enter the international mainstream market; Key materials such as culture media have basically been domesticated; Breakthroughs have been made in a number of special scientific instruments and key equipment processes; The industrial scale has reached more than 10 billion yuan
.
On October 9, Jinan issued Several Policies and Measures on Accelerating the High-quality Development of Biomedicine and Health Industry (hereinafter referred to as "Several Policies"), launching 17 measures in 5 aspects to further upgrade
the original industrial support policies.
According to Jinan City Plan, by 2025, the scale of biomedicine and health industry will exceed 300 billion yuan, of which the scale of biomedical industry will reach 200 billion yuan
.
In order to accelerate the high-quality development of biomedicine and health industry, in fact, since 2018, Jinan has successively formulated and issued the "Jinan Biomedical Industry Development Plan", the 1+N series of policies for industrial strengthening and special policies on accelerating the development of biomedicine and health industry
.
At present, the quality, efficiency and competitiveness of the development of biomedicine and health industry in Jinan are continuously improving, and the industrial scale is also continuing to grow
.
It is reported that in 2021, the city's biomedicine and health industry has achieved operating income of 152.
701 billion yuan, a year-on-year increase of 20.
4%.

In addition, this year, Guangdong Province also issued the Action Plan for the Development of Biomedicine and Health Strategic Pillar Industrial Clusters (2021-2025).

The plan proposes that by 2025, the operating income of biomedicine and health industry will reach 1 trillion yuan
.
With the development of Guangdong's biopharmaceutical industry, more and more innovative drugs with better efficacy and lower price have been approved for clinical marketing
.
.
.
.
.
.
.
In general, biomedicine is a strategic emerging industry that the country focuses on development, and it has obviously become one of the
pillar industries for key development in many places.
In the future, due to the resonance of multiple factors such as favorable policies, influx of talents, capital increase, and increased investment in enterprise R&D, the development of China's biopharmaceutical industry is expected to continue to accelerate, and enter a new round of important strategic opportunities and window periods for innovation and development
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.